医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Edeniq and Global Bio-chem Enter Into Joint Development Agreement

2014年12月02日 PM10:00
このエントリーをはてなブックマークに追加


 

VISALIA, Calif.

Edeniq, Inc. (“Edeniq”), a biorefining and cellulosic technology company, today announced a Joint Development Agreement with Global Bio-chem Technology Group Limited (“Global Bio-chem,” HKG:0809), a leading manufacturer of chemicals from industrial sugars. Following a letter of intent forged in July, the companies further cement their cooperation on developing the lowest cost process for converting corn stover to cellulosic sugars for use in the production of bio-based chemical products.

Ms. Xu Ziyi, Executive Director of Global Bio-chem, said, “China has a large and growing demand for bio-based products. This partnership will allow us to further develop and commercialize our technology platform utilizing the millions of metric tons per year of corn stover available in the Jilin Province, while significantly reducing the production costs of corn stover-based sugar.”

Edeniq and Global Bio-chem plan to integrate their technologies in a commercial demonstration plant at Global Bio-chem’s facility in the Jilin Province of China. Construction has been initiated on the plant, with a target to produce 50,000 metric tons per year of sugars from corn stover. The two companies not only intend to supply the cellulosic sugars to Global Bio-chem for utilization in its existing sugar-based chemical production facilities, but also plan to forge partnerships with other companies to enable the production of a broad array of biochemicals and biofuels from its sugars.

“Edeniq is known for our capital efficient solutions, and this relationship with Global Bio-chem will allow us to quickly expand into the growing markets in China,” said Brian Thome, President and CEO of Edeniq. “Through this partnership, we are further demonstrating our commitment to developing next generation cellulosic technologies and the lowest cost route to efficient biofuel and biochemical production.”

About Edeniq

Edeniq delivers integrated process innovations that unlock sugars. These technological innovations uniquely combine mechanical and biological processes. Edeniq’s capital light and operationally efficient solutions can be easily integrated into existing biorefineries that produce ethanol, other biofuels, biochemicals, and/or bio-based products. Edeniq currently sells or licenses its technologies to biorefineries in the United States and Brazil. Edeniq was founded in 2008 and is headquartered in Visalia, California with locations in Omaha, Nebraska and São Paulo State, Brazil. More information can be found at http://www.edeniq.com.

About Global Bio-chem

Global Bio-chem has been listed on the Main Board of the Stock Exchange of Hong Kong Limited since 2001. The Group is principally engaged in the manufacture and sale, research and development of corn-based biochemical products in the People’s Republic of China (“PRC”). Its products are sold in the PRC and worldwide. Headquartered in Hong Kong and with its production facilities based in various provinces in the PRC, Global Bio-chem is the largest vertically integrated corn-based biochemical product manufacturer in Asia and is one of the leading lysine players in the fermentation industry worldwide. The Group is one of the pioneers in applying corn starch as raw material for the commercial production of polyol chemicals. Global Bio-chem is also the parent company of Global Sweeteners Holdings Limited, one of the largest corn sweeteners producers in the PRC, which is also listed on the Main Board of The Stock Exchange of Hong Kong Limited.

CONTACT

Edeniq, Inc.
Erika Schuetze, 805-540-4318
eschuetze@edeniq.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗